Bismuth subnitrate

Identification

Name
Bismuth subnitrate
Accession Number
DB13209
Type
Small Molecule
Groups
Approved
Description

Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic agent [1]. The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.

Structure
Thumb
Synonyms
  • Bismuth hydroxide nitrate oxide
  • Bismuth nitrate, basic
  • Bismuthum subnitricum
External IDs
C.I. 77169
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Hemorro-dol SupBismuth subnitrate (37.8 mg) + Balsam of Peru (22.6 mg) + Belladonna (11.25 mg) + Benzocaine (50 mg) + Bismuth subcarbonate (86.4 mg) + Boric acid (226.7 mg) + Ephedrine sulfate (2.5 mg) + Zinc oxide (226.7 mg)SuppositoryRectalProduits Francais Labs Inc.1981-12-311997-05-30Canada
Categories
UNII
H19J064BA5
CAS number
1304-85-4
Weight
Average: 1461.98
Monoisotopic: 1461.87284
Chemical Formula
Bi5H9N4O22
InChI Key
QGWDKKHSDXWPET-UHFFFAOYSA-E
InChI
InChI=1S/5Bi.4NO3.9H2O.O/c;;;;;4*2-1(3)4;;;;;;;;;;/h;;;;;;;;;9*1H2;/q5*+3;4*-1;;;;;;;;;;-2/p-9
IUPAC Name
pentabismuth(3+) ion nonahydroxide tetranitrate oxidandiide
SMILES
[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O--].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O

Pharmacology

Indication

Indicated for over-the-counter use as an antacid.

Pharmacodynamics

Bismuth subnitrate acts as an antacid that exert protective effects on the gastric mucosa [1]. In a double-blind endoscopically controlled study, bismuth substrate was demonstrated to be effective for symptomatic relief in duodenal ulcers [2]. In the alcohol model of mucosal injury in the rat, bismuth substrate was shown to be cytoprotective [2]. In a randomized clinical study consisting of patients with H. pylori-associated duodenal ulcer, adjunctive use of colloidal bismuth subnitrate in a short treatment regimen with omeprazole and clarithromycin resulted in improved eradication rate of H. pylori [3].

Mechanism of action

Based on the findings of a clinical investigation in patients with duodenal ulcer disease and healthy volunteers receiving oral bismuth subnitrate tablets, the protective effects of bismuth subnitrate may be secondary to endogenous mucosal prostaglandin (PGE2) production, which is one of the deficient factors observed in peptic ulcer disease [2]. Antacid neutralizing activity of bismuth subnitrate was demonstrated to have a significant postprandial effect on gastric pH [2].

Absorption

Bismuth subnitrate may undergo minimal gastrointestinal absorption which may be potentiated with concomitant administration of sulfhydryl compounds [5] when dissolved in citrate buffer solution [1]. Approximately 0.2% of orally administered bismuth is absorbed systematically from the gastrointestinal tract with the peak plasma concentration typically occurring within 1 hour [5].

Volume of distribution

Bismuth has been shown to accumulate preferentially in the kidneys [1].

Protein binding

Upon accumulation in the kidneys, bismuth may bind to a bismuth-metal binding protein in the kidney [4].

Metabolism

No pharmacokinetic data available.

Route of elimination

Bismuth may undergo both urinary and faecal excretion, however the exact proportion contributed by each route is still unknown [4].

Half life

The distribution half-life of bismuth is approximately 1 to 4 hours, and the elimination half-life is 5 to 11 days [5].

Clearance

No pharmacokinetic data available.

Toxicity

Reported oral dose range for moderate toxicity or possibly lethal toxicity in humans is 0.5-5 g/kg [5]. Nephropathy, encephalopathy, osteoarthropathy, gingivitis, stomatitis and colitis have been attributed to bismuth toxicity in humans [4].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Bismuth subnitrate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth subnitrate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineBismuth subnitrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineBismuth subnitrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineBismuth subnitrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineBismuth subnitrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Bismuth subnitrate.Experimental, Illicit
AcepromazineBismuth subnitrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineBismuth subnitrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Bismuth subnitrate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Bismuth subnitrate.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Bismuth subnitrate.Approved
AlimemazineBismuth subnitrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolBismuth subnitrate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Bismuth subnitrate.Approved
AmphetamineBismuth subnitrate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Bismuth subnitrate.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Bismuth subnitrate.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Bismuth subnitrate.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Bismuth subnitrate.Investigational
AtazanavirBismuth subnitrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Bismuth subnitrate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Bismuth subnitrate.Approved, Investigational
BenzphetamineBismuth subnitrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Bismuth subnitrate.Approved
Bismuth subcitrate potassiumThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Bismuth subnitrate.Approved, Investigational
BL-1020Bismuth subnitrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Bismuth subnitrate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Bismuth subnitrate.Approved
CaptoprilBismuth subnitrate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Bismuth subnitrate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Bismuth subnitrate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Bismuth subnitrate.Approved, Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational, Vet Approved
ChlorphentermineBismuth subnitrate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineBismuth subnitrate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineBismuth subnitrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineBismuth subnitrate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Bismuth subnitrate.Approved, Investigational
CinoxacinBismuth subnitrate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinBismuth subnitrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Bismuth subnitrate.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Bismuth subnitrate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Bismuth subnitrate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Bismuth subnitrate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Bismuth subnitrate.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Bismuth subnitrate.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Bismuth subnitrate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Bismuth subnitrate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth subnitrate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
DasatinibBismuth subnitrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Bismuth subnitrate.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Bismuth subnitrate.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Bismuth subnitrate.Approved
DemeclocyclineBismuth subnitrate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Bismuth subnitrate.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Bismuth subnitrate.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Bismuth subnitrate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Bismuth subnitrate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Bismuth subnitrate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Bismuth subnitrate.Vet Approved
DexmethylphenidateBismuth subnitrate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineBismuth subnitrate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionBismuth subnitrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Bismuth subnitrate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Bismuth subnitrate.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Bismuth subnitrate.Approved
Dipotassium phosphateBismuth subnitrate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineBismuth subnitrate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Bismuth subnitrate.Approved
EnoxacinBismuth subnitrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Bismuth subnitrate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Bismuth subnitrate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Bismuth subnitrate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Bismuth subnitrate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Bismuth subnitrate.Approved
Ferric CarboxymaltoseBismuth subnitrate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateBismuth subnitrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
FleroxacinBismuth subnitrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluasteroneThe bioavailability of Fluasterone can be decreased when combined with Bismuth subnitrate.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Bismuth subnitrate.Approved, Investigational
FlumequineBismuth subnitrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Bismuth subnitrate.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Bismuth subnitrate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Bismuth subnitrate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Bismuth subnitrate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Bismuth subnitrate.Approved, Investigational
FluphenazineBismuth subnitrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Bismuth subnitrate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Bismuth subnitrate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Bismuth subnitrate.Approved
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Bismuth subnitrate.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Bismuth subnitrate.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Bismuth subnitrate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Bismuth subnitrate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Bismuth subnitrate.Approved, Investigational, Withdrawn
FosinoprilBismuth subnitrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
GarenoxacinBismuth subnitrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinBismuth subnitrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
GemifloxacinBismuth subnitrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineBismuth subnitrate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinBismuth subnitrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Bismuth subnitrate.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Bismuth subnitrate.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
HydroxyamphetamineBismuth subnitrate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Bismuth subnitrate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
Iofetamine I-123Bismuth subnitrate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronBismuth subnitrate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranBismuth subnitrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateBismuth subnitrate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidBismuth subnitrate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Bismuth subnitrate.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Bismuth subnitrate.Approved
LevofloxacinBismuth subnitrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineBismuth subnitrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinBismuth subnitrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Bismuth subnitrate.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Bismuth subnitrate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Bismuth subnitrate.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Bismuth subnitrate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Bismuth subnitrate.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Bismuth subnitrate.Approved, Investigational
MephedroneBismuth subnitrate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineBismuth subnitrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Bismuth subnitrate.Approved
MesoridazineBismuth subnitrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineBismuth subnitrate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Bismuth subnitrate.Approved, Vet Approved
MethotrimeprazineBismuth subnitrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineBismuth subnitrate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueBismuth subnitrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateBismuth subnitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Bismuth subnitrate.Experimental
MidomafetamineBismuth subnitrate may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineBismuth subnitrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Bismuth subnitrate is combined with Misoprostol.Approved
MMDABismuth subnitrate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
MoricizineBismuth subnitrate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
MoxifloxacinBismuth subnitrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidBismuth subnitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidBismuth subnitrate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Bismuth subnitrate.Investigational
NemonoxacinBismuth subnitrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
NorfloxacinBismuth subnitrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinBismuth subnitrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Bismuth subnitrate.Investigational
Oxolinic acidBismuth subnitrate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineBismuth subnitrate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Bismuth subnitrate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Bismuth subnitrate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Bismuth subnitrate.Approved
PazufloxacinBismuth subnitrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinBismuth subnitrate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Bismuth subnitrate.Approved
PerazineBismuth subnitrate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerphenazineBismuth subnitrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineBismuth subnitrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidBismuth subnitrate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidBismuth subnitrate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Bismuth subnitrate.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Bismuth subnitrate.Approved, Investigational, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Bismuth subnitrate.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Bismuth subnitrate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Bismuth subnitrate.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Bismuth subnitrate.Approved, Experimental, Investigational
ProchlorperazineBismuth subnitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineBismuth subnitrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineBismuth subnitrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineBismuth subnitrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineBismuth subnitrate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinBismuth subnitrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineBismuth subnitrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineBismuth subnitrate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Bismuth subnitrate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Bismuth subnitrate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Bismuth subnitrate.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
RitobegronBismuth subnitrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinBismuth subnitrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Bismuth subnitrate.Approved
RufloxacinBismuth subnitrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Bismuth subnitrate.Approved
SitafloxacinBismuth subnitrate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateBismuth subnitrate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphate, monobasicBismuth subnitrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Bismuth subnitrate.Approved
SparfloxacinBismuth subnitrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Bismuth subnitrate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Bismuth subnitrate.Approved
TemafloxacinBismuth subnitrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineBismuth subnitrate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiazinamBismuth subnitrate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineBismuth subnitrate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineBismuth subnitrate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineBismuth subnitrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Bismuth subnitrate.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Bismuth subnitrate.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Bismuth subnitrate is combined with Tolevamer.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Bismuth subnitrate.Approved, Vet Approved
TriethylenetetramineBismuth subnitrate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineBismuth subnitrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineBismuth subnitrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinBismuth subnitrate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Bismuth subnitrate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Bismuth subnitrate.Approved
Food Interactions
Not Available

References

General References
  1. Kondo Y, Himeno S, Satoh M, Naganuma A, Nishimura T, Imura N: Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum. Cancer Chemother Pharmacol. 2004 Jan;53(1):33-8. doi: 10.1007/s00280-003-0706-9. Epub 2003 Oct 7. [PubMed:14530870]
  2. Pugh S, Lewin MR: Mechanism of action of Roter (bismuth subnitrate) in patients with duodenal ulcer disease and healthy volunteers. J Gastroenterol Hepatol. 1990 Jul-Aug;5(4):382-6. [PubMed:2129809]
  3. Forne M, Viver JM, Espinos JC, Coll I, Tresserra F, Garau J: Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. Am J Gastroenterol. 1995 May;90(5):718-21. [PubMed:7733075]
  4. Slikkerveer A, de Wolff FA: Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):303-23. [PubMed:2682129]
  5. BISMUTH SUBNITRATE - National Library of Medicine HSDB Database - Toxnet [Link]
External Links
KEGG Drug
D01642
KEGG Compound
C13102
ChemSpider
32699716
ChEBI
31293
Wikipedia
Bismuth_oxynitrate
ATC Codes
A02BX12 — Bismuth subnitrate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuppositoryRectal
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes at 260MSDS
boiling point (°C)Decomposes at 260MSDS
water solubilityInsolubleMSDS
Predicted Properties
PropertyValueSource
logP0.84ChemAxon
pKa (Strongest Basic)-9.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area66.2 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity8.35 m3·mol-1ChemAxon
Polarizability3.28 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as post-transition metal nitrates. These are inorganic compounds in which the largest oxoanion is nitrate, and in which the heaviest atom not in an oxoanion is a post-transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Post-transition metal oxoanionic compounds
Sub Class
Post-transition metal nitrates
Direct Parent
Post-transition metal nitrates
Alternative Parents
Post-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
Substituents
Post-transition metal nitrate / Inorganic post-transition metal salt / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:37 / Updated on July 02, 2018 19:47